Severity assessment of single-dose Oxford-AstraZeneca vaccinated individuals infected with severe acute respiratory syndrome coronavirus 2 in Southeast Bangladesh

Background and Aim: A vaccine program for coronavirus illness (coronavirus disease [COVID-19]) is currently underway in numerous regions of the world, including Bangladesh, but no health data on those who have been vaccinated are available at this time. The study aimed to investigate the health cond...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Eaftekhar Ahmed Rana, Pronesh Dutta, Md. Sirazul Islam, Tanvir Ahmad Nizami, Tridip Das, Sharmin Chowdhury, Goutam Buddha Das
Formato:	article
Lenguaje:	EN
Publicado:	Veterinary World 2021
Materias:	assessment comorbidity coronavirus disease health risk oxford-astrazeneca vaccine Medicine R Medicine (General) R5-920
Acceso en línea:	https://doaj.org/article/ca0f020b2d7e4993a301b4ae208b5348
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:ca0f020b2d7e4993a301b4ae208b5348
record_format	dspace
spelling	oai:doaj.org-article:ca0f020b2d7e4993a301b4ae208b53482021-12-04T07:30:07ZSeverity assessment of single-dose Oxford-AstraZeneca vaccinated individuals infected with severe acute respiratory syndrome coronavirus 2 in Southeast Bangladesh10.14202/IJOH.2021.220-2262455-56732455-8931https://doaj.org/article/ca0f020b2d7e4993a301b4ae208b53482021-12-01T00:00:00Zhttps://www.onehealthjournal.org/Vol.7/No.2/10.pdfhttps://doaj.org/toc/2455-5673https://doaj.org/toc/2455-8931Background and Aim: A vaccine program for coronavirus illness (coronavirus disease [COVID-19]) is currently underway in numerous regions of the world, including Bangladesh, but no health data on those who have been vaccinated are available at this time. The study aimed to investigate the health condition of people who had received their first dose of the Oxford- AstraZeneca vaccine and were infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Materials and Methods: To detect SARS-CoV-2, a standard virological approach, real-time reverse transcriptase-quantitative polymerase chain reaction (RT-qPCR), was used. Several health indicators from vaccinated patients were collected using pre-structured questionnaires during the infection phase. Results: A total of 6146 suspicious samples were analyzed, and 1752 were found to be positive for SARS-CoV-2, with 200 people receiving the first dose of the COVID-19 vaccine. One hundred and sixty-five (82.5%) were not hospitalized among the vaccinated people, and 177 (88.5%) did not have any respiratory problems. Only 8% of patients required further oxygen support, and 199 (99.5%) did not require intensive care unit intervention. Overall, oxygen saturation was recorded at around 96.8% and respiratory difficulties did not extend more than 5 days during the infection period. Among the vaccinated COVID-19-positive people, 113 (56.5%) and 111 (55.5%) had typical physiological taste and smell. Surprisingly, 129 (64.5%) people had diverse comorbidities, with high blood pressure (27.9%) and diabetes (32 [24.8%]) being the most common. The major conclusion of the current study was that 199 (99.5%) of vaccinated patients survived in good health and tested negative for RT-qPCR. Conclusion: According to the findings of this study, administering the first dose of the Oxford-AstraZeneca vaccine considerably reduces health risks during the COVID-19 infection period.Eaftekhar Ahmed RanaPronesh DuttaMd. Sirazul IslamTanvir Ahmad NizamiTridip DasSharmin ChowdhuryGoutam Buddha DasVeterinary Worldarticleassessmentcomorbiditycoronavirus diseasehealth riskoxford-astrazeneca vaccineMedicineRMedicine (General)R5-920ENInternational Journal of One Health, Vol 7, Iss 2, Pp 220-226 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	assessment comorbidity coronavirus disease health risk oxford-astrazeneca vaccine Medicine R Medicine (General) R5-920
spellingShingle	assessment comorbidity coronavirus disease health risk oxford-astrazeneca vaccine Medicine R Medicine (General) R5-920 Eaftekhar Ahmed Rana Pronesh Dutta Md. Sirazul Islam Tanvir Ahmad Nizami Tridip Das Sharmin Chowdhury Goutam Buddha Das Severity assessment of single-dose Oxford-AstraZeneca vaccinated individuals infected with severe acute respiratory syndrome coronavirus 2 in Southeast Bangladesh
description	Background and Aim: A vaccine program for coronavirus illness (coronavirus disease [COVID-19]) is currently underway in numerous regions of the world, including Bangladesh, but no health data on those who have been vaccinated are available at this time. The study aimed to investigate the health condition of people who had received their first dose of the Oxford- AstraZeneca vaccine and were infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Materials and Methods: To detect SARS-CoV-2, a standard virological approach, real-time reverse transcriptase-quantitative polymerase chain reaction (RT-qPCR), was used. Several health indicators from vaccinated patients were collected using pre-structured questionnaires during the infection phase. Results: A total of 6146 suspicious samples were analyzed, and 1752 were found to be positive for SARS-CoV-2, with 200 people receiving the first dose of the COVID-19 vaccine. One hundred and sixty-five (82.5%) were not hospitalized among the vaccinated people, and 177 (88.5%) did not have any respiratory problems. Only 8% of patients required further oxygen support, and 199 (99.5%) did not require intensive care unit intervention. Overall, oxygen saturation was recorded at around 96.8% and respiratory difficulties did not extend more than 5 days during the infection period. Among the vaccinated COVID-19-positive people, 113 (56.5%) and 111 (55.5%) had typical physiological taste and smell. Surprisingly, 129 (64.5%) people had diverse comorbidities, with high blood pressure (27.9%) and diabetes (32 [24.8%]) being the most common. The major conclusion of the current study was that 199 (99.5%) of vaccinated patients survived in good health and tested negative for RT-qPCR. Conclusion: According to the findings of this study, administering the first dose of the Oxford-AstraZeneca vaccine considerably reduces health risks during the COVID-19 infection period.
format	article
author	Eaftekhar Ahmed Rana Pronesh Dutta Md. Sirazul Islam Tanvir Ahmad Nizami Tridip Das Sharmin Chowdhury Goutam Buddha Das
author_facet	Eaftekhar Ahmed Rana Pronesh Dutta Md. Sirazul Islam Tanvir Ahmad Nizami Tridip Das Sharmin Chowdhury Goutam Buddha Das
author_sort	Eaftekhar Ahmed Rana
title	Severity assessment of single-dose Oxford-AstraZeneca vaccinated individuals infected with severe acute respiratory syndrome coronavirus 2 in Southeast Bangladesh
title_short	Severity assessment of single-dose Oxford-AstraZeneca vaccinated individuals infected with severe acute respiratory syndrome coronavirus 2 in Southeast Bangladesh
title_full	Severity assessment of single-dose Oxford-AstraZeneca vaccinated individuals infected with severe acute respiratory syndrome coronavirus 2 in Southeast Bangladesh
title_fullStr	Severity assessment of single-dose Oxford-AstraZeneca vaccinated individuals infected with severe acute respiratory syndrome coronavirus 2 in Southeast Bangladesh
title_full_unstemmed	Severity assessment of single-dose Oxford-AstraZeneca vaccinated individuals infected with severe acute respiratory syndrome coronavirus 2 in Southeast Bangladesh
title_sort	severity assessment of single-dose oxford-astrazeneca vaccinated individuals infected with severe acute respiratory syndrome coronavirus 2 in southeast bangladesh
publisher	Veterinary World
publishDate	2021
url	https://doaj.org/article/ca0f020b2d7e4993a301b4ae208b5348
work_keys_str_mv	AT eaftekharahmedrana severityassessmentofsingledoseoxfordastrazenecavaccinatedindividualsinfectedwithsevereacuterespiratorysyndromecoronavirus2insoutheastbangladesh AT proneshdutta severityassessmentofsingledoseoxfordastrazenecavaccinatedindividualsinfectedwithsevereacuterespiratorysyndromecoronavirus2insoutheastbangladesh AT mdsirazulislam severityassessmentofsingledoseoxfordastrazenecavaccinatedindividualsinfectedwithsevereacuterespiratorysyndromecoronavirus2insoutheastbangladesh AT tanvirahmadnizami severityassessmentofsingledoseoxfordastrazenecavaccinatedindividualsinfectedwithsevereacuterespiratorysyndromecoronavirus2insoutheastbangladesh AT tridipdas severityassessmentofsingledoseoxfordastrazenecavaccinatedindividualsinfectedwithsevereacuterespiratorysyndromecoronavirus2insoutheastbangladesh AT sharminchowdhury severityassessmentofsingledoseoxfordastrazenecavaccinatedindividualsinfectedwithsevereacuterespiratorysyndromecoronavirus2insoutheastbangladesh AT goutambuddhadas severityassessmentofsingledoseoxfordastrazenecavaccinatedindividualsinfectedwithsevereacuterespiratorysyndromecoronavirus2insoutheastbangladesh
_version_	1718372820017217536

Severity assessment of single-dose Oxford-AstraZeneca vaccinated individuals infected with severe acute respiratory syndrome coronavirus 2 in Southeast Bangladesh

Ejemplares similares